Battle for melanoma Market: keysruda of MSD beat yervoy of BMS

Ling fengmuyun: Doctor of pharmaceutical chemistry, Sichuan University, once worked as a special editor on the website of "mystery of life", and won the "best exhibition Report Award" at "ahedd'2014" of Asian drug design conference in 2014 Peyrolizumab, Merck & Co.'s PD-1 inhibitor, beat the best-selling melanoma drug, yervoy, in a head-to-head clinical trial to treat melanoma, according to data from a newly released clinical trial In this head-to-head phase III clinical trial (keynote-006), a total of 834 patients with advanced stage (stage III or stage IV) of unresectable melanoma who had not received more than one systemic treatment before were recruited The experimental results show that keytruda's results are significantly better than yevoy's At the upcoming annual meeting of the Association for cancer research (AACR) next month, MSD will release more data on keytruda in the field of cancer Keytruda (pembrolizumab), the first PD-1 inhibitor on the market in the United States, was approved by the U.S FDA in September 2014 through an accelerated approval process for the treatment of advanced or unresectable melanoma that no longer responds to other drugs In the fourth quarter of 2014, keytruda made $50 million in sales in the United States The results of this experiment will further promote the sales of the drug and consolidate its position in the field of melanoma treatment At present, keytruda is used as a second-line or third-line therapy to treat patients with unresectable or metastatic melanoma, melanoma that has been treated with yervoy but still has progress, or patients whose BRAF V600 gene mutation has been treated with RAF inhibitors (such as zelboraf (vemurafenib) of Roche and tafinlar (dabrafenib) of GlaxoSmithKline) And the new findings are likely to make keytruda a first-line treatment, so keytruda will compete directly with yevoy Yevoy's sales last year were $1.4 billion Previously, analysts had predicted that keytruda's annual sales would be around $140 million, but if it could directly compete with yevoy, the sales could increase a lot However, this does not mean keytruda can break through the encirclement and go to the peak of the field of melanoma treatment In December 2014, opdivo (nivolumab), a PD-1 inhibitor of Bristol Myers Squibb (BMS), was approved by the FDA as the end-line drug for the treatment of melanoma Moreover, as early as July 2014, the drug was approved by Japan, becoming the first PD-1 approved inhibitor in the world, which is used to treat patients with melanoma who cannot be surgically removed, which is keytruda's direct competitor In addition, there are PD-1 / PD-L1 inhibitors in advanced clinical research from other companies, such as Roche's PD-L1 inhibitor mpdl3280a (rg7446), Merck KGaA / Pfizer's msb001718c, and AstraZeneca's PD-L1 monoclonal antibody medi4736 Some analysts have shown that the market for PD-1 / PD-L1 inhibitors may reach US $30 billion Currently, BMS is trying to expand the use of yervoy, for example, in combination with other anticancer drugs, including PD-1 inhibitors such as opdivo and keytruda At the same time, it is also trying to expand the indications of yervoy, which is currently undergoing single drug treatment for prostate cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer, as well as combined treatment with opdivo in melanoma renal cell carcinoma and glioblastoma Of course, mosadon is not weak According to the data released at the 2014 San Antonio Breast Cancer Symposium (SABCS), keytruda showed good antitumor activity in the stage IB study (keynote-012) for the treatment of metastatic triple negative breast cancer (TNBC) The results of a phase IB clinical trial (keynote-013) published by MSD at the 56th Annual Meeting of the American Society of Hematology (ash) in 2014 also showed that keytruda had a good effect in the treatment of recurrent / refractory classic Hodgkin's lymphoma (CHL) and other blood tumors Who can occupy the market in the end, let's wait and see The above article is the author's personal opinion and does not represent the position of this website The intellectual property rights of the published content belong to yaozhi.com If you need to reprint, please indicate the source and the link of this article.